Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;18(3):147-163.
doi: 10.1038/nrg.2016.154. Epub 2016 Dec 28.

Down Syndrome and the Complexity of Genome Dosage Imbalance

Affiliations
Review

Down Syndrome and the Complexity of Genome Dosage Imbalance

Stylianos E Antonarakis. Nat Rev Genet. .

Abstract

Down syndrome (also known as trisomy 21) is the model human phenotype for all genomic gain dosage imbalances, including microduplications. The functional genomic exploration of the post-sequencing years of chromosome 21, and the generation of numerous cellular and mouse models, have provided an unprecedented opportunity to decipher the molecular consequences of genome dosage imbalance. Studies of Down syndrome could provide knowledge far beyond the well-known characteristics of intellectual disability and dysmorphic features, as several other important features, including congenital heart defects, early ageing, Alzheimer disease and childhood leukaemia, are also part of the Down syndrome phenotypic spectrum. The elucidation of the molecular mechanisms that cause or modify the risk for different Down syndrome phenotypes could lead to the introduction of previously unimaginable therapeutic options.

Similar articles

See all similar articles

Cited by 49 articles

See all "Cited by" articles

References

    1. J Biol Chem. 2013 Nov 1;288(44):32050-63 - PubMed
    1. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9962-7 - PubMed
    1. Lancet. 2000 Jan 15;355(9199):165-9 - PubMed
    1. EMBO Mol Med. 2014 Feb;6(2):259-77 - PubMed
    1. Trends Genet. 2001 Feb;17(2):83-8 - PubMed

Publication types

Feedback